SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-17-021878
Filing Date
2017-03-20
Accepted
2017-03-20 20:35:15
Documents
2
Period of Report
2017-03-09

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 15307
2 POA DOCUMENT poa.txt EX-24.3_713261 3607
  Complete submission text file 0001209191-17-021878.txt   20524
Mailing Address 2601 FOURTH AVENUE SUITE 500 SEATTLE WA 98121
Business Address 2601 FOURTH AVENUE SUITE 500 SEATTLE WA 98121 (206) 801-2100
Cascadian Therapeutics, Inc. (Issuer) CIK: 0001412067 (see all company filings)

IRS No.: 260868560 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8731 Services-Commercial Physical & Biological Research

Mailing Address C/O CASCADIAN THERAPEUTICS, INC. 2601 4TH AVE., SUITE 500 SEATTLE WA 98121
Business Address
Walker Luke Nathaniel (Reporting) CIK: 0001701440 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33882 | Film No.: 17702753